Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

EarningsZiihera®Xywav®Positive

AI Analysis

Summary

Jazz Pharmaceuticals reported Q2 2026 revenues of $1.2 billion, up 16% YoY, and raised full-year 2026 guidance. The company is prepared to launch Ziihera in HER2+ first-line gastric cancer following FDA approval, while Xywav generated strong growth with 13% YoY revenue increase and 525 net patient adds.

Financial Highlights

Revenue

$1.2 billion

Guidance

raised

Importance:6/10

Sentiment:

0.75

earningsrevenue growthguidance raiseFDA approval pendingZiiheraXywav

Related Companies

$JAZZ

Read the original article

Published by PR Newswire Biotech on August 3, 2026 8:05 PM

Read Original